

## **CXCL16 is an independent predictor of cardiovascular death and morbidity in acute coronary syndromes**

Thomas Andersen MD<sup>1</sup>, Thor Ueland, PhD<sup>2,3,4,5</sup>, Tatevik Ghukasyan Lalic, MSc<sup>6</sup>, Axel Åkerblom, MD, PhD<sup>6,7</sup>, Maria Bertilsson, MSc<sup>6</sup>, Pål Aukrust, MD, PhD<sup>2,3,4,5,8</sup>, Annika E Michelsen, PhD<sup>2,5</sup>, Stefan K James, MD, PhD<sup>6,7</sup>, Richard C Becker, MD<sup>9</sup>, Robert F Storey, MD, DM<sup>10</sup>, Lars Wallentin, MD, PhD<sup>6,7</sup>, Agneta Siegbahn MD, PhD<sup>11</sup>, Frederic Kontny, MD, PhD<sup>12,13</sup>, for the PLATO Investigators.

**Running title:** CXCL16 in acute coronary syndromes

### **Corresponding author:**

Thomas Andersen

Address: Gerd Ragna Bloch Thorsens gate 8, 4011 Stavanger, Norway.

Phone: 0047 986 43 141.

E-mail: Thomas.andersen@sus.no

**Key words:** Acute Coronary Syndrome, Biomarkers, Inflammation, Risk prediction

**Subject codes:** Acute Coronary Syndromes, Biomarkers, Inflammation, Mortality/Survival

**Word Count:** 6449

**Total number of figures and tables:** 6

**TOC category:** Clinical and population studies

**TOC Subcategory:** Arteriosclerosis, Thrombosis, and Vascular Biology

---

<sup>1</sup> Stavanger University Hospital, Department of Anaesthesiology, Stavanger, Norway

<sup>2</sup> Research Institute of Internal Medicine, the National Hospital, University of Oslo, Oslo, Norway

<sup>3</sup> K.G. Jebsen Inflammatory Research Centre, University of Oslo, Oslo, Norway

<sup>4</sup> K.G. Jebsen – Thrombosis Research and Expertise Centre (TREC), University of Tromsø, Tromsø, Norway

<sup>5</sup> Faculty of medicine, University of Oslo, Oslo, Norway

<sup>6</sup> Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden

<sup>7</sup> Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden

<sup>8</sup> Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway

<sup>9</sup> Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati, Ohio

<sup>10</sup> Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom

<sup>11</sup> Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden

<sup>12</sup> Stavanger University Hospital, Department of Cardiology, Stavanger, Norway

<sup>13</sup> Drammen Heart Centre, Drammen, Norway

## **ABSTRACT**

**Objective:** The chemokine C-X-C motif ligand 16 (CXCL16) is a scavenger receptor for oxidized low-density lipoproteins and involved in inflammation at sites of atherosclerosis. This study aimed to investigate the association of CXCL16 with clinical outcome in patients with acute coronary syndrome (ACS).

**Approach and Results:** Serial measurements of CXCL16 were performed in a subgroup of 5142 patients randomized in the PLATelet inhibition and patient Outcome (PLATO) trial. Associations between CXCL16 and a composite of cardiovascular (CV) death, spontaneous myocardial infarction (sMI) or stroke, and the individual components were assessed by multivariable Cox regression analyses. The hazard ratio (HR) per 50% increase in admission levels of CXCL16 analyzed as continuous variable was 1.64 (95% confidence interval [95%CI]: 1.44-1.88),  $p < 0.0001$ . This association remained statistically significant after adjustment for randomized treatment, clinical variables, C-reactive protein, leukocytes, cystatin C, NT-proBNP, troponin T, Growth Differentiation Factor 15 and other biomarkers; HR 1.23 [1.05-1.45],  $p = 0.0126$ . The admission level of CXCL16 was independently associated with CV death (1.50 [1.17-1.92],  $p = 0.0014$ ), but not with ischemic events alone, in fully adjusted analyses. No statistically independent association was found between CXCL16 measured at 1-month, or change in CXCL16 from admission to 1-month, and clinical outcomes.

**Conclusions:** In patients with ACS, admission level of CXCL16 is independently related to adverse clinical outcomes, mainly driven by an association to CV death. Thus, CXCL16 measurement may enhance risk stratification in patients with this condition.

**Clinicaltrials.gov identifier:** NCT00391872

**Word count:** 235

## ABBREVIATIONS

ACS – Acute coronary syndrome  
Apo-A1 – Apolipoprotein A1  
Apo-B – Apolipoprotein B  
CABG - Coronary artery bypass grafting  
CAD – Coronary artery disease  
CHF - Congestive heart failure  
CKD - Chronic kidney disease  
CRP - C-reactive protein  
CV - Cardiovascular  
CXCL16 – C-X-C ligand 16  
CXCR6 - C-X-C receptor 6  
DM - Diabetes mellitus  
GDF-15 - Growth Differentiation Factor 15  
HR - Hazard ratios  
hs-CRP - High-sensitivity CRP  
hs-TnT - High-sensitivity troponin T  
HT – Hypertension  
IL-6 – Interleukin 6  
IL-18 – Interleukin 18  
ln – Natural logarithm transformed  
LR-test – Likelihood Ratio Test  
NT-proBNP - N-terminal pro-brain natriuretic peptide  
NSTEMI - Non-ST-elevation acute coronary syndrome  
oxLDL - Oxidized low-density lipoproteins  
PAD - Peripheral arterial disease  
PCI - Percutaneous coronary intervention  
PLATO - PLATelet inhibition and patient Outcome trial  
Q1-4 – Quartile 1-4  
sMI - Spontaneous myocardial infarction  
STEMI - ST-elevation acute coronary syndrome  
WBC - Leukocytes

## INTRODUCTION

Ischemic heart disease remains the leading cause of death world-wide despite substantial recent improvements in therapeutic options and risk stratification, including the use of biomarkers.<sup>1</sup> Several inflammatory biomarkers, of which C-reactive protein (CRP) is the most extensively investigated, have been shown to be independent predictors of adverse outcome in patients with coronary artery disease (CAD).<sup>2-6</sup> This includes those with acute coronary syndrome (ACS), and several studies have identified CRP as an independent risk factor for the development of CAD.<sup>2-6</sup>

Chemokines, including the chemokine C-X-C motif ligand 16 (CXCL16), play an important role in atherosclerosis and plaque destabilization. Physiological research indicates that CXCL16, and its receptor C-X-C receptor 6 (CXCR6), are involved in several aspects of atherogenesis. CXCL16 is involved in formation of foam cells through the ability of membrane bound CXCL16 to function as a scavenger receptor for internalizing oxidized lipids.<sup>7</sup> It also promotes leukocyte

infiltration into the atherosclerotic lesion, directly linking lipids to inflammation.<sup>7</sup> It seems that the soluble and membrane form of CXCL16 in part possess different biological functions. Thus, whereas enhanced expression of membrane-bound CXCL16 on endothelial cells, smooth muscle cells, and macrophages within the vessel wall has been shown to promote binding and adhesion of lymphocytes and platelets, soluble CXCL16 acts as a classical chemoattractant for various leukocyte subsets.<sup>8</sup> Soluble CXCL16 may also promote smooth muscle cell proliferation and enhance extracellular matrix remodelling.<sup>9, 10</sup> CXCL16 is released from activated platelets and may also amplify platelet activation, potentially representing a vicious circle that may be operating during plaque destabilization and ACS.<sup>11-14</sup> Taken together CXCL16 seems to be involved in or reflect changes in several important pathways in atherothrombotic disease.

CXCL16 gene polymorphisms have been implicated in increased risk of both CAD, stroke and carotid artery plaque formation, but the results of different studies are partly conflicting, and serum levels of CXCL16 has been suggested as a better marker.<sup>15-20</sup> Several previous studies have found higher serum levels of CXCL16 in ACS versus stable CAD and controls.<sup>17, 21-23</sup> There are, however, only a few prospective studies investigating the use of CXCL16 as a risk marker in CAD<sup>6, 24-27</sup>, and only one of these included patients from an ACS population<sup>6, 24</sup>.

The aims of the present work were to investigate, in a contemporary cohort of ACS patients, the levels of CXCL16 in the acute and chronic phases of ACS and to assess the associations between CXCL16 concentrations and fatal and non-fatal cardiovascular (CV) outcomes, adjusted for other biomarkers reflecting inflammation, kidney dysfunction, myocardial necrosis or dysfunction.

## MATERIAL AND METHODS

The data that support the findings of this study are available from the corresponding author upon reasonable request.

### *Design and study population*

The PLATelet inhibition and patient Outcome trial (PLATO) (NCT00391872) is an international phase III multicenter, double-blind trial of 18624 patients with ACS (i.e. non-ST-elevation ACS (NSTEMI-ACS), or ST-elevation ACS (STEMI-ACS) scheduled for primary percutaneous coronary intervention (PCI)) randomized to either ticagrelor or clopidogrel for 6-12 months on top of optimal medical therapy and invasive strategy as appropriate<sup>28, 29</sup>. The present work was a prespecified substudy in the biomarker project included in the PLATO program.<sup>28</sup> All included patients at selected sites were invited on a consecutive basis to participate in this project which aimed to obtain serial venous blood samples from at least 4000 patients at randomization, discharge and 1 month and at least 2000 at 6 months. The trial adhered to the Helsinki Declaration and informed written consent was obtained from all patients. The study protocol was approved by the local ethics committees.

### *Study endpoints*

The primary efficacy endpoint of the present study was a composite of CV mortality, spontaneous myocardial infarction (sMI) or stroke within 12 months of follow-up and have been defined in an earlier publication.<sup>28, 29</sup> Secondary endpoints

were the individual components of the primary outcome measure. All endpoints were assessed by a central, independent, blinded clinical event adjudication committee.<sup>28</sup>

### *Blood sampling and laboratory analysis*

Baseline venous blood samples were drawn within 24 hours of symptom onset of the index event and before study medication was administered. Serial blood samples were obtained at discharge, 1-month and 6-months follow-up. The samples were centrifuged, and serum and plasma aliquots frozen locally before transport to a central biobank. Measurement of soluble serum CXCL16 was performed by enzyme immunoassay using commercially available matched antibodies (R&D Systems Minneapolis, Minnesota, USA) in a 384-format using the combination of a SELMA (Jena, Germany) pipetting robot and a BioTek (Winooski, Vermont, USA) dispenser/washer (EL406). Absorption was read at 450 nm with wavelength correction set to 540 nm using an ELISA plate reader (Synergy H1 Hybrid, BioTek, Winooski, Vermont, USA). Intra- and interassay coefficient of variation were <10%, and this assay has been validated previously.<sup>24</sup> We have shown that serum CXCL16 measurement to only a minor degree is influenced by 3 freeze and thaw cycles, fasting or non-fasting condition, the timing of blood collection during daytime, and by storage time of frozen samples.<sup>24</sup> Plasma high-sensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP) and cystatin C were analyzed by immunoassays on Cobas® Analytix e601 Immunoanalyzer (Roche Diagnostics, Mannheim, Germany). High-sensitivity CRP (hs-CRP) and leukocytes (WBC) were measured with a spectrophotometric analyzer (Architect, Abbott, Chicago, Illinois, USA). Analysis of Growth Differentiation Factor 15 (GDF-15) was performed with a pre-commercial assay (Roche Diagnostics) using monoclonal murine antibodies. Interleukin 6 (IL-6) was measured using high-sensitivity enzyme-linked immunosorbent assays (Quantikine high sensitivity IL-6 kit, R&D Systems, Minneapolis, Minnesota, USA). Interleukin 18 (IL-18) was measured in EDTA plasma using human IL-18 ELISA (Medical and Biological Laboratories Co. Ltd, Naka-ku, Nagoya, Japan). Oxidized Low-Density Lipoproteins (OxLDL) was measured in EDTA plasma using an enzyme-linked immunosorbent assay (Mercodia AB, Uppsala, Sweden). D-dimer was measured in plasma using a commercial kit (Asserachrom, Stago, Asnieres, France). Apolipoprotein A1 (ApoA1) and Apolipoprotein B (ApoB) was analyzed using an immunoturbidimetric analysis (Architect, Abbott, Chicago, Illinois, USA) using Apolipoprotein A1 and Apolipoprotein B kit from Abbott.

### *Statistical analyses*

Baseline characteristics were presented by quartile groups of CXCL16. Categorical baseline variables were shown as frequencies and percentages and compared by quartile groups of CXCL16 using Chi-square test. Continuous baseline variables were presented as medians and 25<sup>th</sup> to 75<sup>th</sup> percentiles (Q1-Q3) and compared by quartile groups of CXCL16 using Kruskal-Wallis tests. Biomarkers were logarithmic transformed to approximate normal distribution. The relationship between natural log -transformed (ln) CXCL16, baseline characteristics and other biomarkers were analyzed by multivariable linear models. Geometric means were calculated by the antilogarithms of the model-adjusted means and compared between groups using ratios. Correlations between analyzed biomarkers and CXCL16 were assessed by Spearman rank correlation coefficient. Changes in CXCL16 levels over time were analyzed by Wilcoxon signed rank test.

Crude event rates at 12 months as well as Kaplan-Meier event rates were estimated by quartiles of CXCL16 at baseline. Multivariable Cox proportional hazards models were used to assess association between ln(CXCL16) and endpoints, with hazard ratios (HR) based on 50% increase in CXCL16 level. An 8-step incremental model of covariates was used. In **model 0** only randomized treatment was included. **Model 1** added clinical variables; age, sex, body mass index, diabetes mellitus (DM), dyslipidemia, hypertension (HT), chronic kidney disease (CKD), congestive heart failure (CHF), ST-elevation ACS (STE-ACS)/Non-ST-Elevation ACS (NSTEMI-ACS) at randomization, smoking, aspirin at entry, previous atherosclerotic disease (MI, peripheral arterial disease (PAD), coronary artery bypass grafting (CABG), Percutaneous Coronary Intervention (PCI) or non-hemorrhagic stroke). **Model 2** added ln(hs-CRP) and ln(WBC). **Model 3** added ln(cystatin C). **Model 4** included ln(NT-proBNP) and ln(hs-TnT). **Model 5** also included ln(GDF-15). **Model 6** included ln(Apo-A1) and ln(IL-6). The fully adjusted **Model 7** also included ln(D-dimer), ln(IL-18), ln(oxLDL) and ln(Apo-B). The same models were used in assessment of CXCL16 at 1-month. The models used in analyzing change in CXCL16 levels from admission to 1-month were adjusted for both admission levels of CXCL16, and for change in CXCL16 levels from admission to 1-month follow-up, in addition to the models 0-7 described above.

The effects of CXCL16 levels on outcomes in relation to randomized treatment were evaluated using Cox proportional hazards models including CXCL16, randomized treatment and the treatment by CXCL16 interaction term. CXCL16 was included as a continuous, log transformed variable and fitted using restricted cubic splines with 4 knots located at the 5<sup>th</sup>, 35<sup>th</sup>, 65<sup>th</sup> and 95<sup>th</sup> percentiles.

To assess the discriminatory ability of the models, Harrell's C-index was estimated. Models with CXCL16 level added were compared with models without CXCL16 in terms of global model fit using likelihood ratio (LR) tests.

The proportional hazards assumption was assessed by visual inspection of Schoenfeld residual plots. A two-sided p-value of <0.05 was considered statistically significant and there were no adjustments for multiple comparisons, due to the exploratory nature of the study.

All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, North Carolina, USA)

## RESULTS

### *Admission levels of CXCL16 in relation to baseline characteristics and other biomarkers*

A total of 5142 patients were included in the study with a median admission level (Q1-3) of CXCL16 of 5.24 ng/mL (4.51-6.17). Several of the baseline characteristic variables differed significantly across the quartiles of CXCL16 (tab. 1). However, in multivariable regression analysis only female gender, CKD and smoking remained associated with higher CXCL16 values, while increasing age and STE-ACS were associated with lower values (tab. 2A). CXCL16 levels by statin use at inclusion are shown in Suppl.fig I and shows slightly lower levels in the statin group. Spearman correlation analysis revealed a significant positive correlation of CXCL16 with hs-

TnT, NT-proBNP, GDF-15, cystatin C, D-dimer and hs-CRP, but not with WBC, with the strongest correlation with cystatin C ( $R=0.3047$ ,  $p<0.0001$ ) (Suppl.tab. I). Multivariate regression analyzes revealed a strong association of CXCL16 with GDF-15, cystatin C, D-dimer, ApoA1 and ApoB ( $p<0.0001$  for all), whereas no association was seen with NT-proBNP and hs-TnT (tab.2B).

#### *Association of admission levels of CXCL16 with clinical outcome*

Of 5142 patients, 434 (8,4%) suffered a primary event of CV death, sMI or stroke (191 CV deaths [3,7%], 243 sMI [4,7%] and 62 strokes [1,2%]). The crude event rate of the primary composite endpoint per quartile of CXCL16 was 5.6%, 7.3%, 8.7% and 12.1%, respectively. Kaplan-Meier curves, presenting the unadjusted association between quartile groups of CXCL16 and primary endpoint, revealed an increasing risk with higher quartile groups (Fig.1).

The admission level of CXCL16 (with HR per 50% increase in concentration analyzed as continuous variable) was significantly associated with the primary composite endpoint, HR: 1.64 (95%CI: 1.44-1.88),  $p<0.0001$ . This association remained significant in fully-adjusted analyses that, in addition to clinical characteristics, also included hs-CRP, hs-TnT, NT-proBNP, cystatin C, GDF-15, Apo-A1, IL-6, D-dimer, IL-18, oxLDL and Apo-B; HR 1.23 [1.05-1.45],  $p=0.0126$ . This association was mainly driven by the independent relation to CV-death, HR 1.50 [1.17-1.92],  $p=0.0014$ . There was, however, no significant association with sMI or stroke alone. (tab.3) The full stepwise analyses are shown in Suppl.tab II. The restricted cubic spline analysis (Fig. 2) showed that the associations of CXCL16 with the outcomes were non-linear, with relative higher risk of adverse events at high levels of CXCL16. There was no significant interaction between the CXCL16 levels on admission, randomized treatment and the primary composite endpoint ( $p=0.7578$ ).

The CXCL16 level contributed independently to discrimination of the risk of the primary composite endpoint as the C-index increased from 0.703 [0.675-0.731] to 0.706 [0.679-0.734],  $p=0.0115$ . This improvement in discrimination was driven by CV-death, where C-index improved from 0.798 [0.760-0.836] to 0.808 [0.771-0.845],  $p=0.0013$ . C-indices and LR-tests for all endpoints are shown in Suppl.tab III

#### *CXCL16 in the chronic phase*

CXCL16 levels at follow-up were available at discharge in 4576 patients, at 1 month in 4256 patients and at 6 months in 3100 patients. There was an initial increase in the CXCL16 concentrations from admission to a median level (Q1-3) of 5.85 (5.05-6.79) ng/ml at discharge, and 5.31 (4.61-6.19) ng/ml at 1-month ( $p<0.0001$  for both time points vs. baseline) and thereafter a decrease to 5.10 (4.45-5.90) ng/ml at 6 months ( $p<0.01$  vs. baseline) (fig. 3). The median level of CXCL16 at discharge was significantly lower in the ticagrelor group as compared with the clopidogrel group, but this difference was not sustained at 1- and 6-months follow-up (Suppl.tab. IV).

Of the 4234 patients with 1-month measurements and no new CV events since baseline, 240 patients (5.7%) suffered a primary endpoint, of which 85 were CV deaths, 154 sMI and 36 strokes. Crude event rates of the primary composite endpoint per quartile of CXCL16 were 4.2%, 5.8%, 4.6% and 8.1%, respectively. The HR (per 50% increase in CXCL16 concentration) at 1-month for the primary endpoint (in model 0) was 1.53 [1.25-1.86],  $p<0.0001$ . This association remained statistically

significant after adjustment for clinical variables, hs-CRP and WBC (HR 1.30 [1.05-1.61],  $p=0.0144$ ), but not in the fully-adjusted model. The fully-adjusted analysis did not reveal any significant association between CXCL16 levels at 1 month and secondary endpoints (Suppl.tab. V). There was no interaction between CXCL16 values at 1 month, randomized treatment and the primary endpoint ( $p=0.0936$ ).

#### *Change in CXCL16 over time and outcome*

The change in CXCL16 from admission to 1-month and the association to outcomes were assessed in 4191 patients. The HR (per 50% increase of CXCL16 at 1-month for a given value of CXCL16 on admission) for the primary endpoint (in model 0) was 1.27 [0.97-1.67],  $p=0.0843$ . There was no significant association between change in CXCL16 levels from admission to 1-month and outcomes in further adjusted models, neither for the primary endpoint, nor for any secondary endpoints. The full stepwise analyses are included in the suppl.tab VI.

## DISCUSSION

In the present study, serum CXCL16 measured in patients early after admission for ACS was independently associated with the composite of CV death, sMI or stroke. This association remained statistically significant in the fully adjusted analyses, i.e. including both the important prognostic biomarkers NT-proBNP, hs-TnT, cystatin C and GDF-15, and several inflammatory markers (e.g. hsCRP, IL-6, IL-18 and D-dimer) known to be elevated and involved in the pathogenesis of CAD. The relation to outcome was mainly driven by an association with CV-death, while no independent association was seen between CXCL16 levels and other outcome measures. The level of CXCL16 at admission independently contributed to the discrimination between patients concerning the risk of the composite endpoint, again driven by an improved discrimination in the risk of CV death. Our results are supported by the only previous study investigating CXCL16 and risk after ACS, as they also found that CXCL16 predicted long-term mortality in ACS.<sup>24</sup>

CXCL16 measured at 1 month was predictive of subsequent adverse outcome, but this association did not remain significant in the fully-adjusted model. In an earlier study, CXCL16, in combination with osteoprotegerin, was found to predict CV death, MI or heart failure at 3 months.<sup>6</sup> Both this double-biomarker approach, as well as partially different outcome measures and differences in adjustment variables in the statistical analyses, may well explain these results as opposed to our findings.

The predictive value of CXCL16 has also been studied in stable CAD, showing an association with a composite of all-cause death, non-fatal MI, revascularization and hospitalization for angina pectoris during 24 months of follow-up.<sup>25</sup> CXCL16 has furthermore been found to predict the risk of MI in healthy volunteers.<sup>26</sup> Accordingly, CXCL16 may be a new predictor of adverse outcome across the whole spectrum of CAD.

Serial measurements of CXCL16 in the present study showed a rise and fall, with higher values at discharge and a gradual decline over 6 months thereafter. Although the absolute changes are small, the temporal pattern we found is similar to that found in an earlier study.<sup>24</sup> This is in contrast to the pattern found in a small study in STE-ACS patients which found steadily decreasing values after primary PCI.<sup>30</sup> As the fluctuations in CXCL16 levels in our study was generally modest, the



data should be interpreted with caution. The rise from baseline to discharge could potentially indicate a prolonged release of CXCL16 during PCI as a response to ischemia/reperfusion injury and may also reflect the dynamics of CXCL16 with a more gradual increase and decline during acute events, potentially mirroring activation of several up-stream inflammatory pathways.<sup>24, 31</sup> Indeed, while CRP mainly reflects interleukin-6 activation, higher levels of interleukin-1, tumor necrosis factor and interferon- $\gamma$  has been shown to contribute to the release of soluble CXCL16 in endothelial cells and leukocytes.<sup>9, 32</sup>

Change in CXCL16 levels over time has previously been shown to correlate with adverse outcome in stroke patients, but to our knowledge this has never been evaluated in ACS-patients.<sup>31</sup> In stroke patients, the change from day 1 to day 4 was a significant predictor of both all-cause and CV-mortality in adjusted analyses. Our data included only CXCL16 levels on admission, discharge, 1-month and 6-month. Since discharge levels of CXCL16 was significantly associated with randomized treatment, and follow-up was very short with few new adverse events after 6-months, we chose to include only baseline and 1-month levels in our analysis of changes of CXCL16 levels. However, we were not able to confirm any association between change in CXCL16 levels over time and adverse outcome in patients with ACS.

Medical therapy of CAD patients has changed substantially over time. This might have influenced the results of the available studies on CXCL16. Statins (simvastatin and atorvastatin)<sup>9</sup>, angiotensin II receptor blockers (irbesartan)<sup>33</sup> and peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists (rosiglitazone and pioglitazone)<sup>21</sup> have all been shown to decrease the levels of CXCL16 and, as such, may have influenced the results of earlier studies. Still, other studies have reported no difference in levels of CXCL16 between statin-users and others.<sup>21</sup> In our study, patients admitted with prior statin use had lower median levels of CXCL16, although the absolute difference was small and unlikely to be relevant for the associations to clinical outcomes. Furthermore, there were lower levels of CXCL16 at discharge in the ticagrelor group as compared with the clopidogrel group, but this difference was not sustained at 1 and 6 months follow up. However, there were no statistical interaction between CXCL16 levels at any time-point, randomized treatment and outcome. Even though our findings might be without influence of confounding medication, the question of medication use as a bias must be taken into consideration in further studies of CXCL16.

## STRENGTHS AND LIMITATIONS

Our study has the strength of being a large international multicenter trial that includes a broad ACS-population treated according to contemporary guidelines. The long-term storage of the serum samples in the PLATO biobank before CXCL16 measurement may have affected our results. It is difficult to assess the impact of up to 9 years of storage, but the storage time is similar for all samples and hence a potential decay should be similar in all. Moreover, in a previous study, we have to some extent investigated this issue by comparing samples from the initial half of the inclusion period (1995-2001) with the samples from the second half, and found no significant difference.<sup>24</sup> Moreover, our CXCL16 assay have been shown to be robust and only in a minor degree influenced by freeze and thaw cycles, fasting or no fasting condition, and the timing of blood sampling during the day.<sup>24</sup>

CXCL16 levels may be affected by drugs used for ACS or co-morbidities in this population. In our study we have adjusted for randomized treatment and co-morbidities, and have also examined the influence of statins, but still there might be remaining confounders represented by other medication.

## CONCLUSION

In patients with ACS, the admission level of CXCL16 is an independent predictor of the composite of CV death, sMI, or stroke, driven mainly by an association with CV death. The strong relation to fatal outcome remains statistically significant in multivariable analyses adjusted for other potent predictors such as hs-CRP, NT-proBNP, hs-TnT and GDF-15. Thus, CXCL16 may contribute to improved understanding of the pathophysiology of ACS, as well as to enhanced risk stratification beyond that of established biomarkers in patients with this condition.

## ACKNOWLEDGEMENTS

None

## SOURCES OF FUNDING

The PLATO study was funded by AstraZeneca. Support for the analyses, interpretation of results and preparation of the manuscript was provided through funds to the Uppsala Clinical Research Centre as part of the Clinical Study Agreement and by a grant from the Swedish Strategic Research Foundation. Roche Diagnostics, Rotkreuz, Switzerland supported the research by providing GDF-15 assay free of charge. The authors are entirely responsible for the design and conduct of this study; all study analyses, the drafting and editing of the article and its final contents.

## DISCLOSURES

TA: Personal PhD grant from the Western Norway Regional Health Authority

PA, AM, TU: No disclosures

TGL, MB: Institutional Research grant from AstraZeneca and Roche Diagnostics.

AA: Institutional research grant from AstraZeneca and Roche Diagnostics. Advisory board and speaker fees from AstraZeneca

SJ: Institutional Research grant from AstraZeneca and Roche Diagnostics. Honoraria and advisory board fees from AstraZeneca. Grants and personal fees from The Medicines Company and Medtronic, personal fees from Janssen and Bayer outside the submitted work

RB: Scientific Advisory Boards: AstraZeneca, Bayer, CryoLife. DSMB: Portola, Akcea, Ionis.

RS: Received institutional grants from PlaqueTec and AstraZeneca. Consultancy fees from PlaqueTec, Bayer, Bristol-Meyers Squibb/Pfizer, AstraZeneca, Avacta, Novartis, Idorsia, Thromboserin and Haemonetics. Honoraria from AstraZeneca.

LW: Institutional research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Roche Diagnostics, Merck & Co; consulting fees from Abbott; holds two patents involving GDF-15 licensed to Roche Diagnostics.

AS: Institutional research grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline and Roche Diagnostics

FK: Consultancy fees/ honoraria for lectures, advisory board membership, and fee for research work from AstraZeneca; advisory board membership and consultancy fees from Merck & Co, all are considered modest.

## REFERENCES

1. Roffi M, Patrono C, Collet J-P, et al. 2015 esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the european society of cardiology (esc). *European Heart Journal*. 2016;37:267-315
2. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. *J Am Coll Cardiol*. 2003;41:37S-42S
3. Ridker PM. From c-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. *Circulation research*. 2016;118:145-156
4. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *New England Journal of Medicine*. 2017;377:1119-1131
5. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin ptx3 in acute myocardial infarction. *Circulation*. 2004;110:2349-2354
6. Jansson AM, Hartford M, Omland T, Karlsson T, Lindmarker P, Herlitz J, Ueland T, Aukrust P, Caidahl K. Multimarker risk assessment including osteoprotegerin and cxcl16 in acute coronary syndromes. *Arterioscler Thromb Vasc Biol*. 2012;32:3041-3049
7. Izquierdo MC, Martin-Cleary C, Fernandez-Fernandez B, Elewa U, Sanchez-Nino MD, Carrero JJ, Ortiz A. Cxcl16 in kidney and cardiovascular injury. *Cytokine Growth Factor Rev*. 2014;25:317-325
8. Linke B, Meyer Dos Santos S, Picard-Willems B, Keese M, Harder S, Geisslinger G, Scholich K. Cxcl16/cxcr6-mediated adhesion of human peripheral blood mononuclear cells to inflamed endothelium. *Cytokine*. 2017
9. Smith C, Halvorsen B, Otterdal K, Waehre T, Yndestad A, Fevang B, Sandberg WJ, Breland UM, Froland SS, Oie E, Gullestad L, Damas JK, Aukrust P. High levels and inflammatory effects of soluble cxc ligand 16 (cxcl16) in coronary artery disease: Down-regulatory effects of statins. *Cardiovasc Res*. 2008;79:195-203
10. Dahl CP, Husberg C, Gullestad L, et al. Increased production of cxcl16 in experimental and clinical heart failure: A possible role in extracellular matrix remodeling. *Circ Heart Fail*. 2009;2:624-632
11. Seizer P, Stellos K, Selhorst G, Kramer BF, Lang MR, Gawaz M, May AE. Cxcl16 is a novel scavenger receptor on platelets and is associated with acute coronary syndrome. *Thrombosis and haemostasis*. 2011;105:1112-1114
12. Meyer Dos Santos S, Blankenbach K, Scholich K, Dorr A, Monsefi N, Keese M, Linke B, Deckmyn H, Nelson K, Harder S. Platelets from flowing blood attach to the inflammatory chemokine cxcl16 expressed in the endothelium of the human vessel wall. *Thrombosis and haemostasis*. 2015;114:297-312
13. Borst O, Munzer P, Gatidis S, Schmidt EM, Schonberger T, Schmid E, Towhid ST, Stellos K, Seizer P, May AE, Lang F, Gawaz M. The inflammatory chemokine cxc motif ligand 16 triggers

- platelet activation and adhesion via cxc motif receptor 6-dependent phosphatidylinositide 3-kinase/akt signaling. *Circulation research*. 2012;111:1297-1307
14. Bakogiannis C, Sachse M, Stamatelopoulos K, Stellos K. Platelet-derived chemokines in inflammation and atherosclerosis. *Cytokine*. 2017
  15. Jovanovic I, Zivkovic M, Djuric T, Popovic M, Alavantic D, Stankovic A. Cxcl16 in vascular pathology research: From macro effects to micrnas. *Journal of atherosclerosis and thrombosis*. 2015;22:1012-1024
  16. Lundberg GA, Kellin A, Samnegard A, Lundman P, Tornvall P, Dimmeler S, Zeiher AM, Hamsten A, Hansson GK, Eriksson P. Severity of coronary artery stenosis is associated with a polymorphism in the cxcl16/sr-psox gene. *J Intern Med*. 2005;257:415-422
  17. Huang M, Han Y, Zhang X, Pei F, Deng J, Kang J, Yan C. An intron polymorphism in the cxcl16 gene is associated with increased risk of coronary artery disease in chinese han population: A large angiography-based study. *Atherosclerosis*. 2010;210:160-165
  18. Petit SJ, Wise EL, Chambers JC, Sehmi J, Chayen NE, Kooner JS, Pease JE. The cxcl16 a181v mutation selectively inhibits monocyte adhesion to cxcr6 but is not associated with human coronary heart disease. *Arterioscler Thromb Vasc Biol*. 2011;31:914-920
  19. Zivkovic M, Djuric T, Stojkovic L, Jovanovic I, Koncar I, Davidovic L, Veljkovic N, Alavantic D, Stankovic A. Cxcl16 haplotypes in patients with human carotid atherosclerosis: Preliminary results. *Journal of atherosclerosis and thrombosis*. 2015;22:10-20
  20. Tian J, Hu S, Wang F, Yang X, Li Y, Huang C. Pparg, agtr1, cxcl16 and lgals2 polymorphisms are correlated with the risk for coronary heart disease. *Int J Clin Exp Pathol*. 2015;8:3138-3143
  21. Lehrke M, Millington SC, Lefterova M, Cumarantunge RG, Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP. Cxcl16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. *J Am Coll Cardiol*. 2007;49:442-449
  22. Sun Y, Chang Z, Zhang S. Increased serum cxcl16 level is a marker for acute coronary syndromes. *Arch Med Res*. 2008;39:332-337
  23. Zhou F, Wang J, Wang K, Zhu X, Pang R, Li X, Zhu G, Pan X. Serum cxcl16 as a novel biomarker of coronary artery disease in type 2 diabetes mellitus: A pilot study. *Ann Clin Lab Sci*. 2016;46:184-189
  24. Jansson AM, Aukrust P, Ueland T, Smith C, Omland T, Hartford M, Caidahl K. Soluble cxcl16 predicts long-term mortality in acute coronary syndromes. *Circulation*. 2009;119:3181-3188
  25. Tan K, Lu S, Chen Y, et al. Cxc chemokine ligand 16 as a prognostic marker in patients with intermediate coronary artery lesions: A 2-year follow-up study. *Tohoku J Exp Med*. 2011;223:277-283
  26. Laugsand LE, Asvold BO, Vatten LJ, Janszky I, Platou C, Michelsen AE, Arain F, Damas JK, Aukrust P, Ueland T. Soluble cxcl16 and risk of myocardial infarction: The hunt study in norway. *Atherosclerosis*. 2016;244:188-194
  27. Dahl CP, Aukrust P, Nymo SH, Kjekshus J, Cleland JG, McMurray JJ, Wikstrand J, Gullestad L, Ueland T. Prognostic value of cxcl16 in patients with left ventricular systolic dysfunction and heart failure. *International journal of cardiology*. 2013;168:4427-4429
  28. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral p2y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the platelet inhibition and patient outcomes (plato) trial. *Am Heart J*. 2009;157:599-605
  29. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045-1057
  30. Orn S, Breland UM, Mollnes TE, Manhenke C, Dickstein K, Aukrust P, Ueland T. The chemokine network in relation to infarct size and left ventricular remodeling following acute myocardial infarction. *Am J Cardiol*. 2009;104:1179-1183

31. Ueland T, Smedbakken LM, Hallen J, Atar D, Januzzi JL, Halvorsen B, Jensen JK, Aukrust P. Soluble cxcl16 and long-term outcome in acute ischemic stroke. *Atherosclerosis*. 2012;220:244-249
32. Abel S, Hundhausen C, Mentlein R, et al. The transmembrane cxc-chemokine ligand 16 is induced by ifn-gamma and tnf-alpha and shed by the activity of the disintegrin-like metalloproteinase adam10. *J Immunol*. 2004;172:6362-6372
33. Clancy P, Koblar SA, Golledge J. Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. *Atherosclerosis*. 2014;236:108-115

#### HIGHLIGHTS:

- CXCL16 is an inflammatory marker produced locally at sites of inflammation.
- CXCL16 levels are independently associated with the primary composite endpoint of cardiovascular death, spontaneous myocardial infarction or stroke within 12 months after acute coronary syndrome, mainly driven by an association with cardiovascular death.
- Associations between CXCL16 and outcome are adjusted for clinical variables and other biomarkers, including hs-CRP, hs-TnT, NT-proBNP, cystatin C and GDF-15.
- This is the largest study to examine CXCL16 as a risk marker in a broad acute coronary syndrome cohort

#### FIGURE LEGENDS:

Figure 1: Kaplan-Meier estimated event rates of the primary outcome measures per quartile group of the admission levels of CXCL16

Figure 2: Restricted cubic splines of the association between the admission levels of CXCL16 and 12-months estimated event rates of the individual outcome measures in the whole study population

Figure 3: Dynamic changes in CXCL16 levels from admission through 6 month's follow-up

#### APPENDICES:

Supplementary figure and tables

**Table 1:** Baseline characteristics of the study population and biomarkers levels by quartile groups of admission levels of CXCL16

Characteristic	CXCL-16 (ng/mL)				P-value*
	Q1	Q2	Q3	Q4	
	<4.5 n=1286	4.5-5.2 n=1285	5.2-6.2 n=1286	>6.2 n=1285	
<b>Demographics</b>					
Age years, median (Q1-Q3)	61 (54-69)	62 (54-70)	62 (53-71)	64 (55-72)	<.0001
Female	340 (26.4%)	354 (27.5%)	385 (29.9%)	459 (35.7%)	<.0001
Weight kg, median (Q1-Q3)	80 (71-90)	80 (71-90)	80 (70-90)	80 (70-90)	0.5224
BMI kg/m <sup>2</sup> , median (Q1-Q3)	27.5 (24.9-30.4)	27.7 (25.2-30.4)	27.5 (24.8-30.7)	27.8 (25.1-31.1)	0.0849
<b>Risk factor</b>					
Habitual smoker	429 (33.4%)	459 (35.7%)	523 (40.7%)	484 (37.7%)	0.0012
Hypertension	811 (63.1%)	839 (65.3%)	837 (65.1%)	904 (70.4%)	0.0009
Dyslipidemia	538 (41.8%)	537 (41.8%)	533 (41.4%)	563 (43.8%)	0.6088
Diabetes mellitus	247 (19.2%)	262 (20.4%)	293 (22.8%)	341 (26.5%)	<.0001
<b>Medical history</b>					
Angina pectoris	581 (45.2%)	580 (45.1%)	593 (46.1%)	640 (49.8%)	0.0556
Myocardial infarction	213 (16.6%)	248 (19.3%)	260 (20.2%)	287 (22.3%)	0.0029
Congestive heart failure	43 (3.3%)	54 (4.2%)	75 (5.8%)	124 (9.6%)	<.0001
PCI	148 (11.5%)	137 (10.7%)	151 (11.7%)	199 (15.5%)	0.0010
CABG	63 (4.9%)	53 (4.1%)	54 (4.2%)	86 (6.7%)	0.0088
TIA	24 (1.9%)	22 (1.7%)	31 (2.4%)	36 (2.8%)	0.2106
Non-hemorrhagic stroke	36 (2.8%)	42 (3.3%)	54 (4.2%)	43 (3.3%)	0.2628
Peripheral arterial disease	62 (4.8%)	71 (5.5%)	93 (7.2%)	123 (9.6%)	<.0001
Chronic renal disease	15 (1.2%)	22 (1.7%)	51 (4.0%)	92 (7.2%)	<.0001
<b>Type of ACS</b>					
ST-elevation MI	687 (53.4%)	614 (47.8%)	554 (43.1%)	498 (38.8%)	<.0001
<b>Risk scores</b>					
TIMI risk score median (Q1-Q3)	3.0 (2.0-4.0)	4.0 (2.0-5.0)	4.0 (2.0-5.0)	4.0 (3.0-5.0)	<.0001
GRACE risk score median (Q1-Q3)	132 (116-147)	133 (116-151)	133 (117-151)	139 (120-156)	<.0001
<b>Anti-thrombotic treatment in hospital</b>					
Aspirin	1266 (98.4%)	1266 (98.5%)	1273 (99.0%)	1254 (97.6%)	0.0406
Unfractionated heparin	725 (56.4%)	697 (54.2%)	702 (54.6%)	682 (53.1%)	0.4059
LMW heparin	684 (53.2%)	701 (54.6%)	708 (55.1%)	684 (53.2%)	0.7098
Fondaparinux	18 (1.4%)	23 (1.8%)	16 (1.2%)	16 (1.2%)	0.6096
Bivalirudin	16 (1.2%)	19 (1.5%)	18 (1.4%)	23 (1.8%)	0.7066
Gp 2b/3a inhibitor	401 (31.2%)	350 (27.2%)	312 (24.3%)	303 (23.6%)	<.0001
<b>Other medication in hospital</b>					
Beta-blockade	1144 (89.0%)	1128 (87.8%)	1104 (85.8%)	1098 (85.4%)	0.0255
ACE-inhibition and/or ARB	1127 (87.6%)	1119 (87.1%)	1106 (86.0%)	1113 (86.6%)	0.6541
Cholesterol lowering (Statin)	1238 (96.3%)	1216 (94.6%)	1196 (93.0%)	1166 (90.7%)	<.0001
Calcium inhibitor	263 (20.5%)	263 (20.5%)	257 (20.0%)	292 (22.7%)	0.3157
Diuretic	406 (31.6%)	467 (36.3%)	490 (38.1%)	591 (46.0%)	<.0001
Proton pump inhibitor	575 (44.7%)	553 (43.0%)	556 (43.2%)	577 (44.9%)	0.6870
<b>Biomarkers</b>					
Troponin T ng/L median (Q1-Q3)	119.0 (29.3-400.0)	138.0 (37.7-508.0)	198.0 (42.7-651.0)	203.0 (55.8-691.0)	<.0001
NT-proBNP pmol/L median (Q1-Q3)	262.0 (96.0-734.0)	387.0 (126.0-1020)	453.0 (152.0-1163)	641.0 (225.0-1925)	<.0001

Characteristic	CXCL-16 (ng/mL)				P-value*
	Q1	Q2	Q3	Q4	
	<4.5 n=1286	4.5-5.2 n=1285	5.2-6.2 n=1286	>6.2 n=1285	
Cystatin C mg/L median (Q1-Q3)	0.74 (0.61-0.88)	0.80 (0.65-0.95)	0.83 (0.67-1.02)	0.94 (0.76-1.18)	<.0001
GDF-15 ng/ml median (Q1-Q3)	1336 (1031-1772)	1455 (1096-1987)	1562 (1195-2176)	1897 (1344-2797)	<.0001
CRP mg/L median (Q1-Q3)	2.4 (1.2-5.6)	3.1 (1.5-7.0)	3.8 (1.7-9.2)	6.0 (2.5-16.0)	<.0001
IL-6 pg/ml median (Q1-Q3)	2.6 (1.6-4.9)	3.2 (1.9-6.8)	3.5 (1.9-7.5)	4.6 (2.4-10.0)	<.0001

\* P values from the Chi-square test (categorical variables) or Kruskal-Wallis test (continuous variables)  
Abbreviations: BMI: Body Mass Index, PCI: Percutaneous Coronary Intervention, CABG: Coronary Artery Bypass Grafting, TIA: Transient Ischemic Attack, MI: Myocardial Infarction, TIMI: Thrombolysis In Myocardial Infarction, GRACE: Global Registry of Acute Coronary events, LMW: Low Molecular Weight, ACE: Angiotensin Converting Enzyme, ARB: Angiotensin Receptor Blocker, NT-ProBNP: N-terminal ProBrain Natriuretic Protein, GDF-15: Growth Differentiation Factor 15, CRP: C-Reactive Protein, IL-6: Interleukin 6

**Table 2:** Multivariable linear regression analyses of the association of admission levels of CXCL16 with both clinical and laboratory variables

**A: Clinical variables**

<b>Background characteristic</b>	<b>Relative increase*</b>	<b>95% C.I.</b>	<b>P-value</b>
Age, 10-year increase	0.9771	(0.9675 - 0.9867)	<.0001
Female vs male	1.0460	(1.0262 - 1.0662)	<.0001
Diabetes	0.9811	(0.9612 - 1.0014)	0.0680
Congestive heart failure	1.0339	(0.9970 - 1.0721)	0.0720
ST-elevation myocardial infarction	0.9722	(0.9543 - 0.9905)	0.0030
In-hospital invasive	0.9675	(0.9485 - 0.9868)	0.0010
Percutaneous coronary intervention	1.0150	(0.9861 - 1.0447)	0.3127
Chronic renal disease	1.0645	(1.0173 - 1.1139)	0.0069
Hypertension	0.9887	(0.9708 - 1.0069)	0.2223
Coronary artery bypass grafting	1.0120	(0.9733 - 1.0522)	0.5483
Myocardial infarction	0.9952	(0.9716 - 1.0192)	0.6905
Non-hemorrhagic stroke	0.9678	(0.9264 - 1.0110)	0.1415
Peripheral arterial disease	1.0318	(0.9987 - 1.0659)	0.0595
Habitual smoker	1.0353	(1.0157 - 1.0553)	0.0004
Dyslipidemia	1.0036	(0.9865 - 1.0211)	0.6814
Body mass index, $\geq 30$ kg/m <sup>2</sup>	1.0121	(0.9938 - 1.0308)	0.1969
Aspirin at entry	0.9678	(0.9241 - 1.0136)	0.1653

**B: Laboratory variables**

<b>Background Characteristic</b>	<b>Relative increase*</b>	<b>95% C.I.</b>	<b>P-value</b>
NT-proBNP	0.9999	(0.9991 - 1.0006)	0.7770
Troponin T	1.0003	(0.9998 - 1.0009)	0.2495
GDF-15	1.0056	(1.0037 - 1.0075)	<.0001
Cystatin C	1.0178	(1.0144 - 1.0211)	<.0001
hsCRP	1.0012	(1.0004 - 1.0019)	0.0017
WBC	0.9997	(0.9970 - 1.0024)	0.8241
D-dimer	1.0026	(1.0014 - 1.0037)	<.0001
IL-6	1.0019	(1.0007 - 1.0031)	0.0020
IL-18	1.0008	(0.9989 - 1.0027)	0.4196
Ox-LDL	0.9963	(0.9938 - 0.9988)	0.0038
Apo-A1	0.9851	(0.9817 - 0.9884)	<.0001
Apo-B	1.0077	(1.0044 - 1.0109)	<.0001

\*The relative increase is the adjusted geometric mean ratio for 10% increase in biomarker levels.


Abbreviations: NT-ProBNP: N-Terminal ProBrain Natriuretic Peptide, GDF-15: Growth Differentiation Factor 15, hsCRP: High Sensitivity C-Reactive Protein, WBC: White Blood Cell Count; IL-6: Interleukin 6, IL-18: Interleukin 18, Ox-LDL: Oxidized Low-Density Lipoprotein, Apo-A1: Apolipoprotein A1, Apo-B: Apolipoprotein B




**Table 3:** Association of admission levels of CXCL16 with the primary composite endpoint and its individual components. Fully-adjusted multivariable Cox regression analyses with HR per 50% increase of CXCL16 as continuous variable.


<b>Clinical endpoint</b>	<b>HR (95%CI)</b>	<b>P-value</b>
CV death / sMI / stroke	1.23 (1.05 - 1.45)	0.0126
CV death	1.50 (1.17 – 1.92)	0.0014
CV death / sMI	1.20 (1.01 - 1.43)	0.0360
CV death / all MI / stroke	1.25 (1.07 - 1.45)	0.0043
sMI	1.01 (0.82 - 1.25)	0.8980
Stroke	1.18 (0.77 - 1.80)	0.4530

Abbreviations: CV: Cardiovascular; sMI: Spontaneous myocardial infarction



	Months						
Q1	1286	1248	1238	1227	1209	1189	1070
Q2	1285	1240	1220	1196	1182	1142	1009
Q3	1286	1219	1192	1170	1146	1112	956
Q4	1285	1162	1132	1117	1100	1063	933





## SUPPLEMENTAL MATERIALS

### **CXCL16 - Novel, independent predictor of cardiovascular death and morbidity in acute coronary syndrome**

Thomas Andersen MD<sup>1</sup>, Thor Ueland, PhD<sup>2,3,4,5</sup>, Tatevik Ghukasyan Lakic, MSc<sup>6</sup>, Axel Åkerblom, MD, PhD<sup>6,7</sup>, Maria Bertilsson, MSc<sup>6</sup>, Pål Aukrust, MD, PhD<sup>2,3,4,5,8</sup>, Annika E Michelsen, PhD<sup>2,5</sup>, Stefan K James, MD, PhD<sup>6,7</sup>, Richard C Becker, MD<sup>9</sup>, Robert F Storey, MD, DM<sup>10</sup>, Lars Wallentin, MD, PhD<sup>6,7</sup>, Agneta Siegbahn MD, PhD<sup>11</sup>, Frederic Kontny, MD, PhD<sup>12,13</sup>, for the PLATO Investigators.

#### **Contents of the supplementary material**

Major Resources Tables .....	2
Supplementary figure I: Admission CXCL16 level by statin use at inclusion .....	3
Supplementary table I: Spearman correlation of admission levels of CXCL16 with other biomarkers ..	4
Supplementary table II: Multivariable Cox-regression analyses of the association between admission levels of CXCL-16 and outcome .....	5
Supplementary Table III: Prediction performance of models with and without CXCL16 at admission..	7
Supplementary Table IV: CXCL16 levels according to randomized treatment and time point of measurement .....	7
Supplementary table V: Multivariable Cox-regression analyses of the association between 1-month levels of CXCL-16 and outcome .....	8
Supplementary table VI: Multivariable Cox-regression analyses of the association between change in CXCL16 from admission to 1 month and outcome .....	10

---

<sup>1</sup> Stavanger University Hospital, Department of Anaesthesiology, Stavanger, Norway

<sup>2</sup> Research Institute of Internal Medicine, the National Hospital, University of Oslo, Oslo, Norway

<sup>3</sup> K.G. Jebsen Inflammatory Research Centre, University of Oslo, Oslo, Norway

<sup>4</sup> K.G. Jebsen – Thrombosis Research and Expertise Centre (TREC), University of Tromsø, Tromsø, Norway

<sup>5</sup> Faculty of medicine, University of Oslo, Oslo, Norway

<sup>6</sup> Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden

<sup>7</sup> Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden

<sup>8</sup> Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway

<sup>9</sup> Division of Cardiovascular Health and Disease, Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati, Ohio

<sup>10</sup> Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom

<sup>11</sup> Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden

<sup>12</sup> Stavanger University Hospital, Department of Cardiology, Stavanger, Norway

<sup>13</sup> Drammen Heart Centre, Drammen, Norway

## Major Resources Tables

### Animals (in vivo studies)

Species	Vendor or Source	Background Strain	Sex
NA			

### Animal breeding

	Species	Vendor or Source	Background Strain	Other Information
Parent - Male	NA			
Parent - Female	NA			


### Antibodies

Target antigen	Vendor or Source	Catalog #	Working concentration	Lot # (preferred but not required)
CXCL16	R&D Systems	DY1164		

### Cultured Cells

Name	Vendor or Source	Sex (F, M, or unknown)
NA		

Supplementary figure I: Admission CXCL16 level by statin use at inclusion



P-value < 0.0001 (from Mann-Whitney U Test)

**Supplementary table I:** Spearman correlation of admission levels of CXCL16 with other biomarkers

<b>Variable</b>	<b>R</b>	<b>p</b>	<b>n</b>
ln CRP	0.25475	<.0001	4719
ln WBC	0.00972	0.4987	4851
ln GDF-15	0.26255	<.0001	5033
ln hs-TnT	0.10791	<.0001	5032
ln NT-proBNP	0.21054	<.0001	5053
ln cystatin C	0.30472	<.0001	4718
ln D-Dimer	0.20851	<.0001	5055
ln IL6	0.20069	<.0001	5055
ln IL18	0.10056	<.0001	5008
ln OxLDL	-0.02800	0.0465	5055
ln ApoA1	-0.08250	<.0001	4718
ln ApoB	0.08544	<.0001	4718

Abbreviations: CRP: C-Reactive Protein, WBC: White Blood Cell Count, GDF-15: Growth Differentiation Factor 15, TnT: Troponin T, NTproBNP: N-Terminal ProBrain Natriuretic Peptide, IL6: Interleukin 6, IL18: Interleukin 18, OxLDL: Oxidized Low-Density Lipoprotein, ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B



**Supplementary table II:** Multivariable Cox-regression analyses of the association between admission levels of CXCL-16 and outcome

<b>Outcome</b>	<b>Model*</b>	<b>No of events</b>	<b>No of patients</b>	<b>Event rate (%)</b>	<b>HR (95% CI)<sup>†</sup></b>	<b>P-value<sup>‡</sup></b>
CV-death / Spontaneous MI / Stroke	Model 0	434	5142	8.4	1.64 (1.44-1.88)	<.0001
	Model 1	432	5130	8.4	1.51 (1.32-1.74)	<.0001
	Model 2	373	4443	8.4	1.45 (1.24-1.70)	<.0001
	Model 3	373	4442	8.4	1.35 (1.15-1.59)	0.0002
	Model 4	371	4418	8.4	1.32 (1.12-1.55)	0.0008
	Model 5	371	4418	8.4	1.25 (1.06-1.47)	0.0065
	Model 6	364	4379	8.3	1.25 (1.06-1.48)	0.0070
	Model 7	363	4355	8.3	1.23 (1.05-1.45)	0.0126
CV-death / Spontaneous MI	Model 0	388	5142	7.5	1.65 (1.43-1.90)	<.0001
	Model 1	386	5130	7.5	1.51 (1.30-1.75)	<.0001
	Model 2	335	4443	7.5	1.44 (1.22-1.70)	<.0001
	Model 3	335	4442	7.5	1.34 (1.13-1.58)	0.0008
	Model 4	333	4418	7.5	1.30 (1.09-1.54)	0.0027
	Model 5	333	4418	7.5	1.23 (1.04-1.46)	0.0165
	Model 6	326	4379	7.4	1.23 (1.03-1.46)	0.0195
	Model 7	325	4355	7.5	1.20 (1.01-1.43)	0.0360
CV-death	Model 0	191	5142	3.7	2.42 (2.01-2.90)	<.0001
	Model 1	189	5130	3.7	2.23 (1.83-2.71)	<.0001
	Model 2	168	4443	3.8	1.93 (1.54-2.41)	<.0001
	Model 3	168	4442	3.8	1.73 (1.37-2.19)	<.0001
	Model 4	168	4418	3.8	1.66 (1.31-2.10)	<.0001
	Model 5	168	4418	3.8	1.57 (1.24-2.00)	0.0002
	Model 6	162	4379	3.7	1.57 (1.22-2.00)	0.0003
	Model 7	161	4355	3.7	1.50 (1.17-1.92)	0.0014
Spontaneous MI	Model 0	243	5142	4.7	1.21 (1.01-1.45)	0.0394
	Model 1	243	5130	4.7	1.10 (0.92-1.33)	0.3012
	Model 2	209	4443	4.7	1.11 (0.90-1.36)	0.3172
	Model 3	209	4442	4.7	1.06 (0.86-1.31)	0.5656
	Model 4	207	4418	4.7	1.04 (0.85-1.28)	0.6994
	Model 5	207	4418	4.7	1.01 (0.82-1.24)	0.9400
	Model 6	206	4379	4.7	1.01 (0.82-1.25)	0.9180
	Model 7	206	4355	4.7	1.01 (0.82-1.25)	0.8980
Stroke	Model 0	62	5142	1.2	1.46 (1.02-2.10)	0.0404
	Model 1	62	5130	1.2	1.37 (0.94-1.98)	0.0977
	Model 2	51	4443	1.1	1.31 (0.86-1.98)	0.2105
	Model 3	51	4442	1.1	1.19 (0.78-1.81)	0.4269
	Model 4	51	4418	1.2	1.20 (0.78-1.83)	0.4027
	Model 5	51	4418	1.2	1.18 (0.77-1.80)	0.4525
	Model 6	51	4379	1.2	1.19 (0.77-1.82)	0.4341
	Model 7	51	4355	1.2	1.18 (0.77-1.80)	0.4530

<b>Outcome</b>	<b>Model*</b>	<b>No of events</b>	<b>No of patients</b>	<b>Event rate (%)</b>	<b>HR (95% CI)<sup>†</sup></b>	<b>P-value<sup>‡</sup></b>
CV-death / All MI / Stroke	Model 0	508	5142	9.9	1.58 (1.40-1.79)	<.0001
	Model 1	505	5130	9.8	1.48 (1.30-1.69)	<.0001
	Model 2	440	4443	9.9	1.45 (1.25-1.67)	<.0001
	Model 3	440	4442	9.9	1.37 (1.18-1.59)	<.0001
	Model 4	438	4418	9.9	1.34 (1.16-1.56)	0.0001
	Model 5	438	4418	9.9	1.28 (1.10-1.49)	0.0011
	Model 6	431	4379	9.8	1.27 (1.09-1.47)	0.0022
	Model 7	430	4355	9.9	1.25 (1.07-1.45)	0.0043

\* Models include:

Model 0: CXCL16 at admission, adjusted for randomized treatment

Model 1: Model 0 + age, gender, body mass index, diabetes, dyslipidemia, hypertension, chronic renal disease, congestive heart failure, ST-elevation Myocardial Infarction (MI)/non-ST-elevation acute coronary syndrome (ACS) at randomization, smoking, type of ACS, randomized treatment, aspirin at entry and previous (MI/Peripheral artery disease/coronary artery bypass grafting/percutaneous coronary intervention/non-hemorrhagic stroke)

Model 2: Model 1 + hsCRP and white blood cells

Model 3: Model 2 + cystatin C

Model 4: Model 3 + NT-ProBNP and Troponin T

Model 5: Model 4 + GDF-15

Model 6: Model 5 + Apo-A1 and IL-6

Model 7: Model 6 + D-dimer, IL-18, oxLDL and Apo-B

<sup>†</sup> Hazard ratio is per 50% increase in CXCL16

<sup>‡</sup>P-value is for effect of CXCL16

**Supplementary Table III:** Prediction performance of models with and without CXCL16 at admission.

Outcome	C-index (95% CI)		L-R test p-value
	Model* without CXCL-16	Model* with CXCL-16	
CV-death/sMI/Stroke	0.703 (0.675-0.731)	0.706 (0.679-0.734)	0.0115
CV-death/sMI	0.711 (0.682-0.741)	0.714 (0.685-0.743)	0.0338
CV-death	0.798 (0.760-0.836)	0.808 (0.771-0.845)	0.0013
sMI	0.688 (0.651-0.726)	0.688 (0.651-0.726)	0.8978
Stroke	0.739 (0.678-0.800)	0.741 (0.680-0.801)	0.4469
CV-death/All MI/Stroke	0.679 (0.653-0.704)	0.682 (0.656-0.708)	0.0037

Abbreviations: CV - Cardiovascular; sMI - Spontaneous myocardial infarction;

\* Multivariable Cox regression analysis adjusted for clinical variables and all analyzed biomarkers, e.g. fully adjusted model 7

**Supplementary Table IV:** CXCL16 levels according to randomized treatment and time point of measurement

Visit	Treatment	n	Mean (SD)	Geometric mean	Ratio of geometric means (95% CI)	P-value*
Discharge	Ticagrelor	2271	6.074 (1.768)	5.813	0.984 (0.971-0.997)	0.0146
	Clopidogrel	2305	6.145 (1.825)	5.910		
Month 1	Ticagrelor	2113	5.517 (1.435)	5.316	0.999 (0.987-1.012)	0.9000
	Clopidogrel	2143	5.499 (1.496)	5.320		
Month 6	Ticagrelor	1522	5.285 (1.233)	5.148	1.003 (0.990-1.016)	0.6576
	Clopidogrel	1578	5.263 (1.244)	5.133		

\*P-values derived from an analysis of covariance (ANCOVA) model with ln CXCL-16 as dependent variable and ln admission CXCL-16 and randomized treatment (Ticagrelor, Clopidogrel) as independent variables.

**Supplementary table V:** Multivariable Cox-regression analyses of the association between 1-month levels of CXCL-16 and outcome

<b>Outcome</b>	<b>Model*</b>	<b>No of events</b>	<b>No of patients</b>	<b>Event rate (%)</b>	<b>HR (95% CI)<sup>†</sup></b>	<b>P-value<sup>‡</sup></b>
CV-death / Spontaneous MI / Stroke	Model 0	240	4234	5.7	1.53 (1.25-1.86)	<.0001
	Model 1	240	4227	5.7	1.37 (1.11-1.68)	0.0027
	Model 2	220	3760	5.9	1.30 (1.05-1.61)	0.0144
	Model 3	220	3759	5.9	1.22 (0.99-1.52)	0.0682
	Model 4	218	3739	5.8	1.21 (0.98-1.51)	0.0808
	Model 5	218	3739	5.8	1.20 (0.96-1.48)	0.1022
	Model 6	217	3724	5.8	1.19 (0.96-1.48)	0.1059
	Model 7	217	3703	5.9	1.19 (0.96-1.48)	0.1056
CV-death / Spontaneous MI	Model 0	215	4234	5.1	1.55 (1.26-1.91)	<.0001
	Model 1	215	4227	5.1	1.37 (1.10-1.70)	0.0046
	Model 2	197	3760	5.2	1.30 (1.04-1.63)	0.0215
	Model 3	197	3759	5.2	1.21 (0.96-1.52)	0.1003
	Model 4	195	3739	5.2	1.20 (0.96-1.51)	0.1145
	Model 5	195	3739	5.2	1.19 (0.95-1.49)	0.1403
	Model 6	194	3724	5.2	1.19 (0.94-1.49)	0.1409
	Model 7	194	3703	5.2	1.19 (0.94-1.49)	0.1424
CV-death	Model 0	85	4234	2.0	1.74 (1.25-2.43)	0.0010
	Model 1	85	4227	2.0	1.44 (1.02-2.03)	0.0389
	Model 2	81	3760	2.2	1.32 (0.93-1.87)	0.1163
	Model 3	81	3759	2.2	1.17 (0.83-1.65)	0.3814
	Model 4	81	3739	2.2	1.14 (0.80-1.61)	0.4682
	Model 5	81	3739	2.2	1.13 (0.80-1.59)	0.5006
	Model 6	80	3724	2.1	1.15 (0.81-1.64)	0.4227
	Model 7	80	3703	2.2	1.15 (0.81-1.64)	0.4311
Spontaneous MI	Model 0	154	4234	3.6	1.45 (1.13-1.87)	0.0034
	Model 1	154	4227	3.6	1.32 (1.02-1.70)	0.0352
	Model 2	140	3760	3.7	1.29 (0.99-1.69)	0.0621
	Model 3	140	3759	3.7	1.23 (0.94-1.62)	0.1333
	Model 4	138	3739	3.7	1.23 (0.93-1.62)	0.1429
	Model 5	138	3739	3.7	1.22 (0.93-1.60)	0.1599
	Model 6	138	3724	3.7	1.20 (0.91-1.58)	0.1893
	Model 7	138	3703	3.7	1.21 (0.92-1.59)	0.1753
Stroke	Model 0	36	4234	0.9	1.28 (0.76-2.14)	0.3556
	Model 1	36	4227	0.9	1.17 (0.70-1.95)	0.5491
	Model 2	34	3760	0.9	1.14 (0.68-1.93)	0.6189
	Model 3	34	3759	0.9	1.06 (0.63-1.78)	0.8226
	Model 4	34	3739	0.9	1.05 (0.63-1.77)	0.8403
	Model 5	34	3739	0.9	1.05 (0.63-1.77)	0.8456
	Model 6	34	3724	0.9	1.04 (0.63-1.73)	0.8835
	Model 7	34	3703	0.9	1.04 (0.63-1.72)	0.8713

<b>Outcome</b>	<b>Model*</b>	<b>No of events</b>	<b>No of patients</b>	<b>Event rate (%)</b>	<b>HR (95% CI)<sup>†</sup></b>	<b>P-value<sup>‡</sup></b>
CV-death / All MI / Stroke	Model 0	260	4234	6.1	1.42 (1.17-1.72)	0.0003
	Model 1	260	4227	6.2	1.29 (1.06-1.57)	0.0106
	Model 2	236	3760	6.3	1.27 (1.03-1.55)	0.0240
	Model 3	236	3759	6.3	1.20 (0.97-1.47)	0.0893
	Model 4	234	3739	6.3	1.19 (0.97-1.47)	0.1011
	Model 5	234	3739	6.3	1.18 (0.96-1.45)	0.1224
	Model 6	233	3724	6.3	1.17 (0.95-1.43)	0.1452
	Model 7	233	3703	6.3	1.17 (0.95-1.43)	0.1429

\* Models include:

Model 0: CXCL16 at 1 month, adjusted for randomized treatment

Model 1: Model 0 + age, gender, body mass index, diabetes, dyslipidemia, hypertension, chronic renal disease, congestive heart failure, ST-elevation Myocardial Infarction (MI)/non-ST-elevation acute coronary syndrome (ACS) at randomization, smoking, type of ACS, randomized treatment, aspirin at entry and previous (MI/Peripheral artery disease/coronary artery bypass grafting/percutaneous coronary intervention/non-hemorrhagic stroke)

Model 2: Model 1 + hsCRP and white blood cells

Model 3: Model 2 + cystatin C

Model 4: Model 3 + NT-ProBNP and Troponin T

Model 5: Model 4 + GDF-15

Model 6: Model 5 + Apo-A1 and IL-6

Model 7: Model 6 + D-dimer, IL-18, oxLDL and Apo-B

<sup>†</sup> Hazard ratio is per 50% increase in CXCL16

<sup>‡</sup>P-value is for effect of CXCL16

**Supplementary table VI:** Multivariable Cox-regression analyses of the association between change in CXCL16 from admission to 1 month and outcome

<b>Outcome</b>	<b>Model*</b>	<b>No of events</b>	<b>No of patients</b>	<b>Event rate (%)</b>	<b>HR (95% CI)†</b>	<b>P-value‡</b>
CV-death / Sp. MI / Stroke	Model 0	239	4191	5.7	1.27 (0.97-1.67)	0.0843
	Model 1	239	4184	5.7	1.15 (0.88-1.51)	0.3019
	Model 2	219	3746	5.8	1.14 (0.86-1.50)	0.3612
	Model 3	219	3745	5.8	1.10 (0.83-1.44)	0.5184
	Model 4	217	3725	5.8	1.10 (0.83-1.45)	0.5142
	Model 5	217	3725	5.8	1.11 (0.84-1.47)	0.4557
	Model 6	216	3710	5.8	1.12 (0.85-1.48)	0.4151
CV-death / Sp. MI	Model 0	214	4191	5.1	1.25 (0.94-1.67)	0.1311
	Model 1	214	4184	5.1	1.13 (0.85-1.50)	0.4149
	Model 2	196	3746	5.2	1.11 (0.83-1.49)	0.4748
	Model 3	196	3745	5.2	1.07 (0.80-1.43)	0.6666
	Model 4	194	3725	5.2	1.07 (0.80-1.44)	0.6472
	Model 5	194	3725	5.2	1.09 (0.81-1.45)	0.5823
	Model 6	193	3710	5.2	1.10 (0.82-1.47)	0.5342
CV-death	Model 0	84	4191	2.0	1.14 (0.72-1.79)	0.5872
	Model 1	84	4184	2.0	1.00 (0.65-1.55)	0.9955
	Model 2	80	3746	2.1	1.11 (0.71-1.73)	0.6570
	Model 3	80	3745	2.1	1.03 (0.67-1.60)	0.8908
	Model 4	80	3725	2.1	1.03 (0.66-1.61)	0.8983
	Model 5	80	3725	2.1	1.04 (0.67-1.63)	0.8467
	Model 6	79	3710	2.1	1.10 (0.70-1.73)	0.6744
Spontaneous MI	Model 0	154	4191	3.7	1.30 (0.93-1.82)	0.1294
	Model 1	154	4184	3.7	1.20 (0.86-1.69)	0.2909
	Model 2	140	3746	3.7	1.17 (0.82-1.67)	0.3864
	Model 3	140	3745	3.7	1.14 (0.80-1.62)	0.4778
	Model 4	138	3725	3.7	1.14 (0.80-1.64)	0.4635
	Model 5	138	3725	3.7	1.15 (0.81-1.65)	0.4275
	Model 6	138	3710	3.7	1.14 (0.80-1.62)	0.4848
Stroke	Model 0	36	4191	0.9	1.20 (0.60-2.40)	0.5979
	Model 1	36	4184	0.9	1.07 (0.55-2.08)	0.8422
	Model 2	34	3746	0.9	1.08 (0.55-2.12)	0.8341
	Model 3	34	3745	0.9	1.03 (0.53-2.02)	0.9202
	Model 4	34	3725	0.9	1.01 (0.52-1.96)	0.9771
	Model 5	34	3725	0.9	1.01 (0.52-1.96)	0.9734
	Model 6	34	3710	0.9	1.01 (0.52-1.95)	0.9751
Model 7	34	3689	0.9	1.01 (0.52-1.94)	0.9846	

<b>Outcome</b>	<b>Model*</b>	<b>No of events</b>	<b>No of patients</b>	<b>Event rate (%)</b>	<b>HR (95% CI)<sup>†</sup></b>	<b>P-value<sup>‡</sup></b>
CV-death / All MI / Stroke	Model 0	259	4191	6.2	1.21 (0.93-1.57)	0.1592
	Model 1	259	4184	6.2	1.10 (0.85-1.43)	0.4487
	Model 2	235	3746	6.3	1.12 (0.86-1.46)	0.4067
	Model 3	235	3745	6.3	1.08 (0.83-1.41)	0.5507
	Model 4	233	3725	6.3	1.09 (0.83-1.43)	0.5254
	Model 5	233	3725	6.3	1.10 (0.84-1.44)	0.4717
	Model 6	232	3710	6.3	1.11 (0.85-1.45)	0.4288
	Model 7	232	3689	6.3	1.11 (0.85-1.45)	0.4390

\* Models include:

Model 0: Change in CXCL16 from admission to 1 month, adjusted for CXCL16 at admission and randomized treatment

Model 1: Model 0 + age, gender, body mass index, diabetes, dyslipidemia, hypertension, chronic renal disease, congestive heart failure, ST-elevation Myocardial Infarction (MI)/non-ST-elevation acute coronary syndrome (ACS) at randomization, smoking, type of ACS, randomized treatment, aspirin at entry and previous (MI/Peripheral artery disease/coronary artery bypass grafting/percutaneous coronary intervention/non-hemorrhagic stroke)

Model 2: Model 1 + hsCRP and white blood cells

Model 3: Model 2 + cystatin C

Model 4: Model 3 + NT-ProBNP and Troponin T

Model 5: Model 4 + GDF-15

Model 6: Model 5 + Apo-A1 and IL-6

Model 7: Model 6 + D-dimer, IL-18, oxLDL and Apo-B

<sup>†</sup> Hazard ratio is per 50% increase in CXCL16

<sup>‡</sup>P-value is for effect of CXCL16